Overall, it appears that elevated HBP activity and O-GlcNAcylation likely supports constitutive NF-κB signaling in AML patients alluding to the therapeutic potential of targeting NF-κB O-GlcNAcylation as a promising approach to treat AML. This evidence concerns the gene NFKB1 and acute myeloid leukemia.